Stephen M Rowland

US Patent:

7037332, May 2, 2006

Filed:

Mar 15, 2001

Appl. No.:

09/808867

Inventors:

Michael John Bradley Kutryk - Toronto, CA
Stephen Maxwell Rowland - Miami FL, US

Assignee:

Orbus Medical Technologies, Inc. - Fort Lauderdale FL

International Classification:

A61F 2/06

US Classification:

623 148, 623 146, 623 2376, 600 36

Abstract:

A medical device coated with one or more antibodies and one or more layers of a matrix is disclosed. The antibodies or fragments thereof react with an endothelial cell surface antigen. Also disclosed are compositions and methods for producing the medical device. The matrix coating the medical device may be composed of a synthetic material, such as a fullerene, or a naturally occurring material. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote the adherence of cells captured in vivo on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following adherence to the medical device, the cells differentiate and proliferate on the medical device. The antibodies may be different types of monoclonal antibodies. By facilitating adherence of cells to the surface of the medical device, the disclosed methods and compositions will decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.

US Patent:

7803183, Sep 28, 2010

Filed:

Apr 26, 2004

Appl. No.:

10/832106

Inventors:

Michael John Bradley Kutryk - Toronto, CA
Stephen Maxwell Rowland - Miami FL, US

Assignee:

OrbusNeich Medical, Inc. - Fort Lauderale FL

International Classification:

A61F 2/06

US Classification:

623 146

Abstract:

A medical device with a coating for capturing target cells in vivo is provided. In particular, the medical device is coated with at least one layer of matrix and a layer of antibodies, antibody fragments or combinations thereof, which bind with specificity to mature or progenitor endothelial cells at various developmental stages to form an endothelial cell layer on the surface of the device. The coated medical device can be, for example, a stent or a synthetic graft and is useful in therapy of diseases such as restenosis, atherosclerosis, and thromboembolic complications.

US Patent:

8460367, Jun 11, 2013

Filed:

Nov 15, 2006

Appl. No.:

11/560352

Inventors:

Stephen M. Rowland - Miami FL, US
Sherri Parker - Sunrise FL, US

Assignee:

OrbusNeich Medical, Inc. - Fort Lauderdale FL

International Classification:

A61F 2/06

US Classification:

623 148, 623 142, 623 146, 623 2376

Abstract:

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

US Patent:

20030229393, Dec 11, 2003

Filed:

Feb 6, 2003

Appl. No.:

10/360567

Inventors:

Michael Kutryk - Toronto, CA
Robert Cottone - Davie FL, US
Stephen Rowland - Miami FL, US
Michael Kuliszewski - Mississauga, CA

International Classification:

A61F002/06

US Classification:

623/001460, 523/113000

Abstract:

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

US Patent:

20040039441, Feb 26, 2004

Filed:

May 20, 2003

Appl. No.:

10/442669

Inventors:

Stephen Rowland - Miami FL, US
Ike Juman - Davie FL, US
Robert Cottone - Davie FL, US
David Camp - Fort Lauderdale FL, US

International Classification:

A61F002/06

US Classification:

623/001420, 427/002100

Abstract:

A drug eluting medical device is provided for implanting into vessels or luminal structures within the body of a patient. The coated medical device, such as a stent, vascular, or synthetic graft comprises a coating consisting of a controlled-release matrix of a bioabsorbable, biocompatible, bioerodible, biodegradable, nontoxic material, such as a Poly(DL-Lactide-co-Glycolide) polymer, and at least one pharmaceutical substance, or bioactive agent incorporated within the matrix or layered within layers of matrix. In particular, the drug eluting medical device when implanted into a patient, delivers the drugs or bioactive agents within the matrix to adjacent tissues in a controlled and desired rate depending on the drug and site of implantation.

US Patent:

20050025752, Feb 3, 2005

Filed:

Apr 30, 2004

Appl. No.:

10/835767

Inventors:

Michael Kutryk - York, CA
Robert Cottone - Davie FL, US
Stephen Rowland - Miami FL, US

International Classification:

A61K048/00
C12N005/08
C12N015/85

US Classification:

424093210, 435455000, 435366000

Abstract:

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and a therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

US Patent:

20050271701, Dec 8, 2005

Filed:

Mar 10, 2005

Appl. No.:

11/076731

Inventors:

Robert Cottone - Davie FL, US
Stephen Rowland - Miami FL, US
Horace Davis - Coral Springs FL, US
Michael Kutryk - Ontario, CA

Assignee:

Orbus Medical Technologies, Inc. - Fort Lauderdale FL

International Classification:

A61F002/00

US Classification:

424426000

Abstract:

A medical device for implantation into vessels or luminal structures within the body is provided. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

US Patent:

20060121012, Jun 8, 2006

Filed:

Apr 29, 2005

Appl. No.:

11/119291

Inventors:

Michael Kutryk - Ontario, CA
Robert Cottone - Davie FL, US
Stephen Rowland - Miami FL, US

Assignee:

ORBUS MEDICAL TECHNOLOGIES, INC. - Fort Lauderdale FL

International Classification:

A61F 2/06
A61F 2/82
A61K 48/00
C12N 15/87

US Classification:

424093210, 623001460, 623001410, 435455000

Abstract:

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.